Jul 12, 2019

Primary central nervous system lymphoma: Novel precision therapies

Critical Reviews in Oncology/hematology
Patrizia MondelloFrancesco Bertoni

Abstract

Primary central nervous system lymphoma (PCNSL) is a rare and aggressive form of diffuse large B-cell lymphoma. The frontline treatment with high-dose methotrexate based immunochemotherapy is not curative for the majority of patients. Gene expression profiling and next-generation sequencing have recently provided plethora of data shedding light on pathogenic mechanisms sustain PCNSL and identifying potential vulnerable mechanisms to be explored therapeutically. Here, we review established molecular drivers of PCNSL and targeted drugs that may change the current therapeutic paradigm.

  • References
  • Citations1

References

  • We're still populating references for this paper, please check back later.
  • References
  • Citations1

Citations

Mentioned in this Paper

Antineoplastic Chemotherapy Protocols
Gene Expression
Pharmacologic Substance
Massively-Parallel Sequencing
Individualized Medicine
Central Nervous System Neoplasms, Primary
Primary Central Nervous System Lymphoma
High-Throughput Nucleotide Sequencing
Methotrexate
Reticulosarcoma

Related Feeds

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Related Papers

Arquivos de neuro-psiquiatria
Elizabete Maria Pereira de Andrade CairesAntônio Alberto Zambon
Current Opinion in Neurology
Lauren E Abrey
© 2020 Meta ULC. All rights reserved